| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 16 | 2016 | 58 | 3.270 |
Why?
|
| Liver Neoplasms | 26 | 2013 | 334 | 3.100 |
Why?
|
| Liver | 26 | 2009 | 1118 | 2.640 |
Why?
|
| Microwaves | 13 | 2009 | 31 | 2.120 |
Why?
|
| Catheter Ablation | 21 | 2009 | 229 | 2.040 |
Why?
|
| Interleukin-12 | 8 | 2007 | 75 | 1.420 |
Why?
|
| Adenocarcinoma | 12 | 2012 | 475 | 1.250 |
Why?
|
| Cryosurgery | 10 | 2008 | 53 | 1.230 |
Why?
|
| Ablation Techniques | 3 | 2013 | 33 | 1.120 |
Why?
|
| General Surgery | 10 | 2016 | 95 | 1.080 |
Why?
|
| Genetic Therapy | 9 | 2003 | 291 | 0.850 |
Why?
|
| Colorectal Neoplasms | 8 | 2013 | 560 | 0.850 |
Why?
|
| Laparoscopy | 6 | 2013 | 237 | 0.830 |
Why?
|
| Plasmids | 5 | 2007 | 258 | 0.780 |
Why?
|
| Gene Transfer Techniques | 7 | 2002 | 173 | 0.770 |
Why?
|
| Postoperative Complications | 7 | 2016 | 1615 | 0.720 |
Why?
|
| Workload | 5 | 2016 | 103 | 0.720 |
Why?
|
| Transducers | 3 | 2007 | 21 | 0.650 |
Why?
|
| Hot Temperature | 4 | 2007 | 152 | 0.640 |
Why?
|
| Pancreatectomy | 3 | 2016 | 129 | 0.610 |
Why?
|
| Venous Thromboembolism | 2 | 2015 | 116 | 0.570 |
Why?
|
| Melanoma | 7 | 2018 | 335 | 0.570 |
Why?
|
| DNA, Complementary | 7 | 2007 | 251 | 0.570 |
Why?
|
| Pancreatic Neoplasms | 6 | 2009 | 332 | 0.550 |
Why?
|
| Hospital Costs | 1 | 2016 | 117 | 0.520 |
Why?
|
| Finite Element Analysis | 7 | 2009 | 55 | 0.520 |
Why?
|
| Animals | 44 | 2012 | 20877 | 0.520 |
Why?
|
| Internship and Residency | 5 | 2016 | 596 | 0.520 |
Why?
|
| Operative Time | 1 | 2015 | 45 | 0.510 |
Why?
|
| Gallbladder Neoplasms | 2 | 2012 | 6 | 0.500 |
Why?
|
| Interleukin-2 | 5 | 2018 | 133 | 0.500 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2007 | 101 | 0.500 |
Why?
|
| Cholecystitis | 1 | 2014 | 12 | 0.490 |
Why?
|
| Cholecystectomy | 2 | 2014 | 79 | 0.480 |
Why?
|
| Equipment Design | 10 | 2009 | 500 | 0.480 |
Why?
|
| Body Temperature | 4 | 2007 | 116 | 0.480 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 124 | 0.470 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2013 | 163 | 0.470 |
Why?
|
| Humans | 84 | 2020 | 68525 | 0.460 |
Why?
|
| Choledochal Cyst | 1 | 2012 | 4 | 0.450 |
Why?
|
| Job Satisfaction | 2 | 2016 | 62 | 0.440 |
Why?
|
| Robotics | 1 | 2013 | 56 | 0.440 |
Why?
|
| Bile Ducts | 1 | 2012 | 59 | 0.430 |
Why?
|
| Pancreatic Ducts | 1 | 2012 | 76 | 0.430 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 253 | 0.430 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2020 | 34 | 0.430 |
Why?
|
| Swine | 14 | 2007 | 672 | 0.420 |
Why?
|
| Genetic Vectors | 4 | 2007 | 311 | 0.420 |
Why?
|
| Female | 56 | 2018 | 38015 | 0.420 |
Why?
|
| Electrodes | 6 | 2007 | 147 | 0.410 |
Why?
|
| Antibodies, Monoclonal | 6 | 2018 | 510 | 0.400 |
Why?
|
| Models, Biological | 9 | 2009 | 981 | 0.400 |
Why?
|
| Embolization, Therapeutic | 2 | 2013 | 150 | 0.400 |
Why?
|
| Electric Conductivity | 2 | 2009 | 87 | 0.400 |
Why?
|
| Cattle | 8 | 2009 | 475 | 0.380 |
Why?
|
| Breast Neoplasms | 9 | 2007 | 1533 | 0.350 |
Why?
|
| Colonoscopy | 2 | 2009 | 156 | 0.350 |
Why?
|
| Pancreatic Fistula | 1 | 2009 | 23 | 0.340 |
Why?
|
| Spinal Fusion | 3 | 2000 | 90 | 0.340 |
Why?
|
| Heat-Shock Proteins | 5 | 1996 | 69 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2018 | 444 | 0.340 |
Why?
|
| Thermography | 3 | 2007 | 20 | 0.340 |
Why?
|
| Plethysmography, Impedance | 1 | 2007 | 17 | 0.310 |
Why?
|
| Electric Impedance | 2 | 2007 | 131 | 0.310 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 95 | 0.300 |
Why?
|
| Aged | 28 | 2020 | 14842 | 0.300 |
Why?
|
| Burnout, Professional | 1 | 2008 | 64 | 0.290 |
Why?
|
| Sigmoidoscopy | 1 | 2006 | 38 | 0.290 |
Why?
|
| Male | 38 | 2020 | 37281 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2016 | 2323 | 0.280 |
Why?
|
| Education, Medical, Graduate | 4 | 2016 | 214 | 0.280 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2006 | 38 | 0.280 |
Why?
|
| Electromagnetic Phenomena | 1 | 2006 | 25 | 0.280 |
Why?
|
| Cholecystectomy, Laparoscopic | 3 | 2014 | 59 | 0.280 |
Why?
|
| Killer Cells, Natural | 5 | 2004 | 94 | 0.280 |
Why?
|
| Immunotherapy | 4 | 2005 | 212 | 0.270 |
Why?
|
| Calorimetry | 1 | 2005 | 21 | 0.270 |
Why?
|
| Middle Aged | 31 | 2020 | 21119 | 0.270 |
Why?
|
| Adult | 30 | 2020 | 21375 | 0.270 |
Why?
|
| Splenic Neoplasms | 1 | 2004 | 5 | 0.260 |
Why?
|
| Thermometers | 1 | 2005 | 13 | 0.260 |
Why?
|
| Biomarkers, Tumor | 3 | 1995 | 508 | 0.260 |
Why?
|
| Work Schedule Tolerance | 3 | 2016 | 18 | 0.250 |
Why?
|
| Neoplasms | 6 | 2003 | 1660 | 0.250 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 63 | 0.250 |
Why?
|
| Equipment Failure Analysis | 4 | 2006 | 121 | 0.250 |
Why?
|
| Antineoplastic Agents | 5 | 2009 | 1070 | 0.250 |
Why?
|
| Personnel Staffing and Scheduling | 3 | 2016 | 64 | 0.250 |
Why?
|
| Mice, Inbred BALB C | 6 | 2009 | 532 | 0.250 |
Why?
|
| Endocardium | 1 | 2004 | 101 | 0.240 |
Why?
|
| Time-to-Treatment | 2 | 2016 | 117 | 0.240 |
Why?
|
| Liver Cirrhosis | 1 | 2007 | 301 | 0.240 |
Why?
|
| Portal Vein | 2 | 2001 | 46 | 0.240 |
Why?
|
| Models, Cardiovascular | 1 | 2004 | 133 | 0.240 |
Why?
|
| Frozen Sections | 2 | 2007 | 14 | 0.230 |
Why?
|
| Computer Simulation | 8 | 2009 | 705 | 0.230 |
Why?
|
| Lymphatic Metastasis | 3 | 2009 | 274 | 0.230 |
Why?
|
| Mice | 13 | 2012 | 8472 | 0.230 |
Why?
|
| In Vitro Techniques | 5 | 2007 | 765 | 0.220 |
Why?
|
| Antigens, Neoplasm | 4 | 1995 | 132 | 0.220 |
Why?
|
| Melanoma, Experimental | 2 | 2001 | 95 | 0.220 |
Why?
|
| Models, Theoretical | 1 | 2006 | 384 | 0.220 |
Why?
|
| Laparoscopes | 3 | 1997 | 8 | 0.220 |
Why?
|
| Neoplasms, Experimental | 2 | 2001 | 118 | 0.220 |
Why?
|
| Bile Duct Neoplasms | 2 | 2016 | 39 | 0.220 |
Why?
|
| Interferon-gamma | 5 | 2004 | 241 | 0.220 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 201 | 0.220 |
Why?
|
| Treatment Outcome | 13 | 2016 | 7028 | 0.220 |
Why?
|
| Transfection | 7 | 2001 | 782 | 0.210 |
Why?
|
| Surgical Procedures, Operative | 4 | 2016 | 124 | 0.210 |
Why?
|
| Skin | 2 | 2007 | 451 | 0.210 |
Why?
|
| Colonic Neoplasms | 3 | 2012 | 299 | 0.210 |
Why?
|
| Nephrectomy | 2 | 2005 | 103 | 0.210 |
Why?
|
| Intraoperative Care | 2 | 2000 | 91 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 8 | 2002 | 852 | 0.210 |
Why?
|
| Sarcoma | 3 | 2005 | 70 | 0.200 |
Why?
|
| Hepatic Artery | 1 | 2001 | 25 | 0.200 |
Why?
|
| B7-1 Antigen | 1 | 2001 | 20 | 0.200 |
Why?
|
| Diathermy | 2 | 2006 | 5 | 0.200 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2016 | 348 | 0.200 |
Why?
|
| Immunoconjugates | 1 | 2001 | 26 | 0.190 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 1996 | 61 | 0.190 |
Why?
|
| Duodenal Neoplasms | 1 | 2020 | 9 | 0.190 |
Why?
|
| Neurofibroma | 1 | 2020 | 11 | 0.190 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 10 | 0.190 |
Why?
|
| Vulvar Neoplasms | 1 | 2000 | 21 | 0.190 |
Why?
|
| Mass Screening | 1 | 2006 | 837 | 0.190 |
Why?
|
| Cancer Vaccines | 2 | 1997 | 61 | 0.190 |
Why?
|
| Immunologic Factors | 2 | 2005 | 87 | 0.190 |
Why?
|
| Neoplasm, Residual | 3 | 2007 | 33 | 0.190 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 46 | 0.190 |
Why?
|
| Neurofibromatosis 1 | 1 | 2020 | 39 | 0.190 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 64 | 0.180 |
Why?
|
| Lymphocytes | 4 | 1999 | 228 | 0.180 |
Why?
|
| Vaccines, DNA | 2 | 2007 | 9 | 0.180 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2008 | 52 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.170 |
Why?
|
| Neoplasm Staging | 8 | 2018 | 799 | 0.170 |
Why?
|
| United States | 9 | 2020 | 7335 | 0.170 |
Why?
|
| Radiography, Interventional | 1 | 1999 | 49 | 0.170 |
Why?
|
| Risk Factors | 6 | 2020 | 5719 | 0.170 |
Why?
|
| Stents | 3 | 2016 | 657 | 0.160 |
Why?
|
| Survival Analysis | 5 | 2009 | 714 | 0.160 |
Why?
|
| Contraindications | 2 | 2013 | 52 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2020 | 168 | 0.160 |
Why?
|
| Retrospective Studies | 11 | 2016 | 7264 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 91 | 0.160 |
Why?
|
| Spleen | 3 | 2004 | 301 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2020 | 346 | 0.150 |
Why?
|
| Intestinal Obstruction | 2 | 2009 | 36 | 0.150 |
Why?
|
| Body Water | 2 | 2007 | 35 | 0.150 |
Why?
|
| Career Choice | 2 | 2008 | 98 | 0.150 |
Why?
|
| Neoplasm Metastasis | 4 | 2009 | 306 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2009 | 129 | 0.150 |
Why?
|
| Lymphocyte Activation | 2 | 1996 | 397 | 0.150 |
Why?
|
| Carcinoma in Situ | 2 | 2007 | 45 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 1996 | 756 | 0.150 |
Why?
|
| Vaccines | 1 | 1996 | 21 | 0.140 |
Why?
|
| Prognosis | 7 | 2009 | 2093 | 0.140 |
Why?
|
| Risk Assessment | 7 | 2020 | 2004 | 0.140 |
Why?
|
| Secondary Care Centers | 1 | 2016 | 2 | 0.140 |
Why?
|
| Aged, 80 and over | 11 | 2016 | 4843 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 778 | 0.140 |
Why?
|
| Lymph | 1 | 1996 | 8 | 0.140 |
Why?
|
| Incidence | 4 | 2015 | 1582 | 0.140 |
Why?
|
| Policy Making | 1 | 2016 | 51 | 0.140 |
Why?
|
| Hospitals, Community | 1 | 2016 | 64 | 0.140 |
Why?
|
| Appendectomy | 1 | 2016 | 47 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 67 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 581 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 1996 | 129 | 0.130 |
Why?
|
| Appendicitis | 1 | 2016 | 55 | 0.130 |
Why?
|
| Immunohistochemistry | 7 | 2003 | 1174 | 0.130 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 1995 | 12 | 0.130 |
Why?
|
| Cholestasis | 1 | 2016 | 90 | 0.130 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1995 | 17 | 0.130 |
Why?
|
| Interferon-alpha | 1 | 1995 | 46 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 624 | 0.130 |
Why?
|
| Combined Modality Therapy | 7 | 2009 | 951 | 0.130 |
Why?
|
| Ultrasonography | 4 | 2005 | 453 | 0.130 |
Why?
|
| Cholecystitis, Acute | 1 | 2014 | 4 | 0.120 |
Why?
|
| Temperature | 6 | 2005 | 340 | 0.120 |
Why?
|
| Receptor, ErbB-2 | 1 | 1995 | 128 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2001 | 265 | 0.120 |
Why?
|
| Tissue Distribution | 2 | 2005 | 282 | 0.120 |
Why?
|
| Neoplasm Transplantation | 3 | 2004 | 160 | 0.120 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1993 | 15 | 0.120 |
Why?
|
| Glycoproteins | 1 | 1995 | 238 | 0.120 |
Why?
|
| Physicians | 2 | 2016 | 324 | 0.120 |
Why?
|
| Electroporation | 1 | 2013 | 11 | 0.120 |
Why?
|
| Mastectomy, Segmental | 2 | 2007 | 63 | 0.110 |
Why?
|
| Time Factors | 7 | 2008 | 4655 | 0.110 |
Why?
|
| Tumor Burden | 2 | 2018 | 132 | 0.110 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 8 | 0.110 |
Why?
|
| Abdominal Pain | 1 | 2014 | 97 | 0.110 |
Why?
|
| Fellowships and Scholarships | 2 | 2011 | 127 | 0.110 |
Why?
|
| Necrosis | 5 | 2004 | 239 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 3 | 2016 | 119 | 0.110 |
Why?
|
| Perception | 1 | 2013 | 189 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2015 | 621 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2001 | 1172 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2009 | 2077 | 0.100 |
Why?
|
| Medical Audit | 1 | 2011 | 44 | 0.100 |
Why?
|
| Skin Neoplasms | 2 | 2007 | 375 | 0.100 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 30 | 0.100 |
Why?
|
| Hospitals | 1 | 2013 | 265 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1991 | 28 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 503 | 0.100 |
Why?
|
| CD8 Antigens | 2 | 2002 | 25 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 199 | 0.100 |
Why?
|
| CD4 Antigens | 2 | 2002 | 42 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2013 | 322 | 0.100 |
Why?
|
| Lung | 1 | 1996 | 849 | 0.100 |
Why?
|
| Probability | 2 | 2008 | 244 | 0.100 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2003 | 85 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2004 | 66 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 442 | 0.090 |
Why?
|
| Survival Rate | 5 | 2018 | 1055 | 0.090 |
Why?
|
| Gastroenterology | 1 | 2011 | 98 | 0.090 |
Why?
|
| Program Development | 1 | 2011 | 240 | 0.090 |
Why?
|
| Cytokines | 3 | 2012 | 866 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 1993 | 595 | 0.090 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2009 | 17 | 0.090 |
Why?
|
| Octreotide | 1 | 2009 | 21 | 0.090 |
Why?
|
| Problem-Based Learning | 1 | 2010 | 72 | 0.090 |
Why?
|
| Algorithms | 3 | 2011 | 1194 | 0.090 |
Why?
|
| Lymph Nodes | 2 | 2001 | 258 | 0.090 |
Why?
|
| Immunologic Memory | 1 | 2009 | 75 | 0.090 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 104 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2014 | 1329 | 0.080 |
Why?
|
| Luciferases | 2 | 1999 | 105 | 0.080 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 14 | 0.080 |
Why?
|
| Thermal Conductivity | 2 | 2007 | 24 | 0.080 |
Why?
|
| Disposable Equipment | 1 | 2008 | 12 | 0.080 |
Why?
|
| Cholangiocarcinoma | 1 | 2008 | 20 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2011 | 403 | 0.080 |
Why?
|
| Biopsy | 4 | 2007 | 539 | 0.080 |
Why?
|
| Drainage | 1 | 2009 | 133 | 0.080 |
Why?
|
| Body Size | 1 | 2008 | 39 | 0.080 |
Why?
|
| Physicians, Women | 1 | 2008 | 23 | 0.080 |
Why?
|
| Mentors | 1 | 2008 | 81 | 0.080 |
Why?
|
| Surgery Department, Hospital | 1 | 2008 | 19 | 0.080 |
Why?
|
| Hand | 1 | 2008 | 90 | 0.080 |
Why?
|
| Water Loss, Insensible | 1 | 2007 | 3 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2007 | 20 | 0.080 |
Why?
|
| Occupational Health | 1 | 2008 | 41 | 0.080 |
Why?
|
| Injections, Intralesional | 1 | 2007 | 25 | 0.080 |
Why?
|
| Sleep Deprivation | 1 | 2008 | 81 | 0.080 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2008 | 75 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2007 | 48 | 0.070 |
Why?
|
| Administration, Cutaneous | 1 | 2007 | 56 | 0.070 |
Why?
|
| Unnecessary Procedures | 1 | 2007 | 49 | 0.070 |
Why?
|
| Efficiency, Organizational | 1 | 2007 | 61 | 0.070 |
Why?
|
| Wisconsin | 1 | 2006 | 30 | 0.070 |
Why?
|
| Blood Loss, Surgical | 1 | 2007 | 79 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2018 | 1341 | 0.070 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 63 | 0.070 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 3256 | 0.070 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2006 | 16 | 0.070 |
Why?
|
| Breast | 1 | 2007 | 137 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2007 | 110 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 104 | 0.070 |
Why?
|
| Sex Factors | 2 | 2007 | 1265 | 0.070 |
Why?
|
| Reference Values | 1 | 2007 | 579 | 0.070 |
Why?
|
| Students, Medical | 1 | 2008 | 210 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2007 | 206 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 237 | 0.070 |
Why?
|
| Pancreatitis | 1 | 1988 | 279 | 0.070 |
Why?
|
| Computer-Aided Design | 1 | 2006 | 101 | 0.070 |
Why?
|
| Phantoms, Imaging | 1 | 2006 | 189 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2005 | 82 | 0.070 |
Why?
|
| CD4-CD8 Ratio | 1 | 2004 | 5 | 0.070 |
Why?
|
| Transplantation, Heterotopic | 1 | 2004 | 7 | 0.070 |
Why?
|
| Lumbar Vertebrae | 2 | 1996 | 112 | 0.060 |
Why?
|
| Blood | 1 | 2004 | 40 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 1996 | 8 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 53 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2005 | 46 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 929 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 40 | 0.060 |
Why?
|
| Injections | 1 | 2004 | 119 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 2004 | 334 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 370 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2001 | 2790 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 40 | 0.060 |
Why?
|
| Injections, Intradermal | 1 | 2003 | 6 | 0.060 |
Why?
|
| Accreditation | 2 | 2016 | 72 | 0.060 |
Why?
|
| Hematologic Tests | 1 | 2003 | 24 | 0.060 |
Why?
|
| DNA Primers | 2 | 2001 | 302 | 0.060 |
Why?
|
| Hernia, Inguinal | 1 | 2003 | 21 | 0.060 |
Why?
|
| Lead | 1 | 2003 | 45 | 0.060 |
Why?
|
| Endometriosis | 1 | 2003 | 56 | 0.060 |
Why?
|
| Motivation | 1 | 2007 | 561 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2001 | 79 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 2 | 2014 | 136 | 0.060 |
Why?
|
| Cold Temperature | 1 | 2003 | 90 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2002 | 13 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2004 | 1663 | 0.060 |
Why?
|
| Lymphatic Diseases | 1 | 2002 | 27 | 0.050 |
Why?
|
| Cations | 1 | 2002 | 51 | 0.050 |
Why?
|
| Transgenes | 1 | 2002 | 92 | 0.050 |
Why?
|
| Young Adult | 2 | 2018 | 5708 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2008 | 652 | 0.050 |
Why?
|
| Kidney | 2 | 2005 | 945 | 0.050 |
Why?
|
| Radiography | 3 | 2004 | 572 | 0.050 |
Why?
|
| Killer Cells, Lymphokine-Activated | 3 | 2005 | 11 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 492 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2003 | 154 | 0.050 |
Why?
|
| Reoperation | 2 | 2007 | 467 | 0.050 |
Why?
|
| Sensitivity and Specificity | 5 | 2003 | 1753 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 186 | 0.050 |
Why?
|
| Viscera | 1 | 2001 | 16 | 0.050 |
Why?
|
| CD28 Antigens | 1 | 2001 | 12 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 30 | 0.050 |
Why?
|
| Constriction | 1 | 2001 | 37 | 0.050 |
Why?
|
| Abatacept | 1 | 2001 | 17 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 25 | 0.050 |
Why?
|
| Lymphokines | 1 | 2001 | 49 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2001 | 45 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 89 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2001 | 49 | 0.050 |
Why?
|
| Aneurysm, Ruptured | 1 | 2001 | 40 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2004 | 2550 | 0.050 |
Why?
|
| Biolistics | 2 | 1999 | 5 | 0.050 |
Why?
|
| Kinetics | 1 | 2002 | 1047 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 80 | 0.050 |
Why?
|
| Keratins | 1 | 2000 | 48 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2009 | 3702 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2000 | 91 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2001 | 230 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2001 | 160 | 0.050 |
Why?
|
| Interleukin-18 | 1 | 1999 | 16 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2001 | 489 | 0.040 |
Why?
|
| DNA | 1 | 2002 | 597 | 0.040 |
Why?
|
| Models, Animal | 3 | 2005 | 252 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 219 | 0.040 |
Why?
|
| Punctures | 1 | 1999 | 35 | 0.040 |
Why?
|
| Phenotype | 1 | 2002 | 946 | 0.040 |
Why?
|
| Thymidine | 1 | 1999 | 32 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 710 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 742 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1999 | 114 | 0.040 |
Why?
|
| Laparotomy | 1 | 1999 | 65 | 0.040 |
Why?
|
| Mice, Inbred DBA | 1 | 1999 | 120 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 307 | 0.040 |
Why?
|
| Viral Proteins | 1 | 1999 | 149 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2009 | 125 | 0.040 |
Why?
|
| Gene Expression | 1 | 2001 | 770 | 0.040 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 2 | 1995 | 4 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2004 | 2222 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 1032 | 0.040 |
Why?
|
| Serpins | 1 | 1999 | 205 | 0.040 |
Why?
|
| Ileal Neoplasms | 1 | 1997 | 5 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 429 | 0.040 |
Why?
|
| Cushing Syndrome | 1 | 1997 | 7 | 0.040 |
Why?
|
| Formaldehyde | 1 | 1997 | 48 | 0.040 |
Why?
|
| Somatostatin | 1 | 1997 | 36 | 0.040 |
Why?
|
| Carcinoid Tumor | 1 | 1997 | 20 | 0.040 |
Why?
|
| Indium Radioisotopes | 1 | 1997 | 19 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 507 | 0.040 |
Why?
|
| Mastectomy | 1 | 1997 | 56 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1999 | 226 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 1997 | 142 | 0.040 |
Why?
|
| Histology | 1 | 1996 | 7 | 0.040 |
Why?
|
| Hemostasis, Surgical | 2 | 2007 | 18 | 0.040 |
Why?
|
| Cell Death | 1 | 1997 | 329 | 0.040 |
Why?
|
| Back Pain | 1 | 1996 | 30 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2008 | 536 | 0.040 |
Why?
|
| Gamma Rays | 1 | 1996 | 64 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 181 | 0.040 |
Why?
|
| Illinois | 1 | 2016 | 5 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 1993 | 110 | 0.040 |
Why?
|
| Cystadenoma, Mucinous | 1 | 1996 | 7 | 0.040 |
Why?
|
| CD2 Antigens | 1 | 1996 | 8 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 1425 | 0.030 |
Why?
|
| Bone Transplantation | 1 | 1996 | 43 | 0.030 |
Why?
|
| Thrombosis | 1 | 1997 | 218 | 0.030 |
Why?
|
| Blood Cells | 1 | 1996 | 27 | 0.030 |
Why?
|
| Particle Size | 1 | 1996 | 201 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 1996 | 37 | 0.030 |
Why?
|
| Gold | 1 | 1996 | 76 | 0.030 |
Why?
|
| Glutathione | 1 | 1997 | 343 | 0.030 |
Why?
|
| Radio Waves | 2 | 2007 | 21 | 0.030 |
Why?
|
| Sheep | 1 | 1996 | 128 | 0.030 |
Why?
|
| Hospital Administration | 1 | 2016 | 43 | 0.030 |
Why?
|
| Intervertebral Disc Displacement | 1 | 1995 | 17 | 0.030 |
Why?
|
| Cell Count | 1 | 1996 | 248 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 218 | 0.030 |
Why?
|
| Cell Division | 2 | 1993 | 541 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 1995 | 118 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1995 | 26 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 411 | 0.030 |
Why?
|
| Fatigue | 1 | 2016 | 132 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1995 | 144 | 0.030 |
Why?
|
| Endosonography | 1 | 2016 | 177 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 467 | 0.030 |
Why?
|
| Lymphoma | 1 | 1995 | 116 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 170 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 658 | 0.030 |
Why?
|
| Regional Blood Flow | 2 | 2005 | 168 | 0.030 |
Why?
|
| Patient Safety | 1 | 2016 | 202 | 0.030 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1993 | 41 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 1995 | 369 | 0.030 |
Why?
|
| Intraoperative Period | 2 | 2007 | 62 | 0.030 |
Why?
|
| Intestinal Polyps | 1 | 2012 | 15 | 0.030 |
Why?
|
| Immunologic Surveillance | 1 | 2012 | 10 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2012 | 14 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 521 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 1995 | 307 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2005 | 349 | 0.030 |
Why?
|
| Teratoma | 1 | 1992 | 22 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1993 | 138 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 780 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 94 | 0.030 |
Why?
|
| Contrast Media | 1 | 2016 | 594 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 1992 | 61 | 0.030 |
Why?
|
| Levamisole | 1 | 1991 | 4 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 378 | 0.030 |
Why?
|
| Virginia | 1 | 2011 | 45 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2012 | 116 | 0.030 |
Why?
|
| Methods | 1 | 1991 | 156 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2009 | 1849 | 0.030 |
Why?
|
| Health Priorities | 1 | 1991 | 23 | 0.030 |
Why?
|
| Radiotherapy | 1 | 1991 | 86 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2005 | 567 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 1992 | 267 | 0.020 |
Why?
|
| Research | 1 | 1991 | 214 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2008 | 2356 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2010 | 69 | 0.020 |
Why?
|
| Selection Bias | 1 | 2009 | 23 | 0.020 |
Why?
|
| Goals | 1 | 2010 | 65 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 125 | 0.020 |
Why?
|
| Risk | 2 | 2004 | 563 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1039 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 177 | 0.020 |
Why?
|
| Pancreatic Juice | 1 | 1988 | 9 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 1173 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1988 | 14 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1991 | 1139 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 272 | 0.020 |
Why?
|
| Relative Value Scales | 1 | 2007 | 8 | 0.020 |
Why?
|
| Energy Transfer | 1 | 2007 | 25 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 319 | 0.020 |
Why?
|
| Medicine | 1 | 2007 | 51 | 0.020 |
Why?
|
| Specialization | 1 | 2007 | 66 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2007 | 16 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 546 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2004 | 1465 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2007 | 123 | 0.020 |
Why?
|
| Decision Making | 1 | 2010 | 410 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 447 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2007 | 149 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 1030 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 791 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2008 | 295 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2008 | 303 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2007 | 118 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 31 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2005 | 16 | 0.020 |
Why?
|
| Curriculum | 1 | 2010 | 575 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2005 | 17 | 0.020 |
Why?
|
| Education, Medical | 1 | 2007 | 147 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2005 | 43 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1985 | 164 | 0.020 |
Why?
|
| Angioedema | 1 | 2005 | 41 | 0.020 |
Why?
|
| Life Style | 1 | 2007 | 338 | 0.020 |
Why?
|
| Materials Testing | 1 | 2006 | 263 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2005 | 238 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 41 | 0.020 |
Why?
|
| Culture Techniques | 1 | 2003 | 65 | 0.020 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 2003 | 1 | 0.010 |
Why?
|
| Sus scrofa | 1 | 2003 | 74 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2003 | 76 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 2004 | 53 | 0.010 |
Why?
|
| Pedigree | 1 | 2003 | 159 | 0.010 |
Why?
|
| Sound | 1 | 2003 | 16 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 2003 | 51 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2003 | 50 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2003 | 57 | 0.010 |
Why?
|
| Laser Therapy | 1 | 2003 | 54 | 0.010 |
Why?
|
| Rheology | 1 | 2002 | 25 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2003 | 396 | 0.010 |
Why?
|
| Palliative Care | 1 | 2005 | 271 | 0.010 |
Why?
|
| Electromagnetic Fields | 1 | 2002 | 66 | 0.010 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2001 | 63 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2002 | 275 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1999 | 105 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 1548 | 0.010 |
Why?
|
| Software | 1 | 2002 | 418 | 0.010 |
Why?
|
| Buthionine Sulfoximine | 1 | 1997 | 10 | 0.010 |
Why?
|
| Melphalan | 1 | 1997 | 15 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 1015 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1997 | 57 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 1997 | 35 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1997 | 77 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 2331 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 1997 | 57 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1997 | 26 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1997 | 137 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1997 | 174 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1997 | 150 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1997 | 172 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1997 | 231 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1997 | 291 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1996 | 141 | 0.010 |
Why?
|
| Pancreas | 1 | 1996 | 225 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 5300 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2001 | 3185 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 689 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1996 | 880 | 0.010 |
Why?
|
| Endoscopy | 1 | 1996 | 464 | 0.010 |
Why?
|
| Tryptophan Oxygenase | 1 | 1991 | 2 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1991 | 22 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1991 | 71 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1992 | 235 | 0.010 |
Why?
|
| Monocytes | 1 | 1991 | 210 | 0.010 |
Why?
|
| Child | 1 | 2001 | 6400 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1991 | 626 | 0.010 |
Why?
|
| Apoptosis | 1 | 1996 | 1640 | 0.010 |
Why?
|
| Adolescent | 1 | 2001 | 8903 | 0.010 |
Why?
|